Brivaracetam: First Global Approval

被引：21

作者：

Markham, Anthony ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2016年 / 76卷 / 04期

关键词：

PARTIAL-ONSET SEIZURES; SYNAPTIC VESICLE PROTEIN; PLACEBO-CONTROLLED TRIAL; ADJUNCTIVE BRIVARACETAM; DOUBLE-BLIND; PHASE-III; SV2A LIGAND; EFFICACY; EPILEPSY; ADULTS;

D O I：

10.1007/s40265-016-0555-6

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Brivaracetam (Briviact((R))), a 4-n-propyl analogue of levetiracetam developed by UCB Pharma, has been approved in the EU as an adjunctive therapy for the treatment of partial-onset seizures. Brivaracetam binds to synaptic vesicle glycoprotein 2a (SV2A) in the brain with greater selectivity and 15- to 30-fold higher affinity than levetiracetam, as demonstrated in preclinical models, and has demonstrated efficacy in reducing the frequency of partial onset seizures in clinical trials. This article summarizes the milestones in the development of brivaracetam leading to this first approval for use as adjunctive therapy for uncontrolled partial-onset seizures in adults with epilepsy.

引用

页码：517 / 522

页数：6

共 20 条

[1]

Beydoun A, 2015, 69 ANN M AM EP SOC

[2] Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double-blind, placebo-controlled trial [J].

Biton, Victor ;

Berkovic, Samuel F. ;

Abou-Khalil, Bassel ;

Sperling, Michael R. ;

Johnson, Martin E. ;

Lu, Sarah .

EPILEPSIA, 2014, 55 (01) :57-66

[3]

European Medicines Agency, 2016, BRIV BRIV SUMM PROD

[4] Adjunctive brivaracetam for refractory partial-onset seizures A randomized, controlled trial [J].

French, J. A. ;

Costantini, C. ;

Brodsky, A. ;

von Rosenstiel, P. .

NEUROLOGY, 2010, 75 (06) :519-525

[5] Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties [J].

Gillard, Michel ;

Fuks, Bruno ;

Leclercq, Karine ;

Matagne, Alain .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2011, 664 (1-3) :36-44

[6] A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures [J].

Klein, Pavel ;

Schiemann, Jimmy ;

Sperling, Michael R. ;

Whitesides, John ;

Liang, Wei ;

Stalvey, Tracy ;

Brandt, Christian ;

Kwan, Patrick .

EPILEPSIA, 2015, 56 (12) :1890-1898

[7] Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial [J].

Kwan, Patrick ;

Trinka, Eugen ;

Van Paesschen, Wim ;

Rektor, Ivan ;

Johnson, Martin E. ;

Lu, Sarah .

EPILEPSIA, 2014, 55 (01) :38-46

[8] Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A [J].

Matagne, A. ;

Margineanu, D-G ;

Kenda, B. ;

Michel, P. ;

Klitgaard, H. .

BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (08) :1662-1671

[9] Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action [J].

Nicolas, Jean-Marie ;

Hannestad, Jonas ;

Holden, Daniel ;

Kervyn, Sophie ;

Nabulsi, Nabeel ;

Tytgat, Dominique ;

Huang, Yiyun ;

Chanteux, Hugues ;

Staelens, Ludovicus ;

Matagne, Alain ;

Mathy, Francois-Xavier ;

Mercier, Joel ;

Stockis, Armel ;

Carson, Richard E. ;

Klitgaard, Henrik .

EPILEPSIA, 2016, 57 (02) :201-209

[10] Brivaracetam, a Novel Antiepileptic Drug: Is it Effective and Safe? Results from One Phase III Randomized Trial [J].

Pack, Alison M. .

EPILEPSY CURRENTS, 2014, 14 (04) :196-198

← 1 2 →